This positions its platform as a rapidly evolving engine for next-generation genetic medicine
The platform combines internally developed technologies, strategic partnerships, and external AI capabilities
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
Access to genomic testing, not therapy cost, is the biggest challenge
Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone
New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Subscribe To Our Newsletter & Stay Updated